Patient-related Risk Factors for Nausea and Vomiting With Standard Antiemetics in Patients With Cancer Receiving Carboplatin: A Retrospective Study

被引：3

作者：

Nasu, Izumi ^{[1
,2
]}

Shimano, Rena ^{[1
]}

Kawazoe, Hitoshi ^{[2
,3
]}

Nakamura, Tomonori ^{[2
,3
]}

Miura, Yuji ^{[4
]}

Takano, Toshimi ^{[4
]}

Hayashi, Masahiro ^{[1
]}

机构：

[1] Toranomon Gen Hosp, Dept Pharm, Tokyo, Japan

[2] Keio Univ, Div Pharmaceut Care Sci, Grad Sch Pharmaceut Sci, Tokyo, Japan

[3] Keio Univ, Div Pharmaceut Care Sci, Ctr Social Pharm & Pharmaceut Care Sci, Fac Pharm, Tokyo, Japan

[4] Toranomon Gen Hosp, Dept Med Oncol, Tokyo, Japan

来源：

CLINICAL THERAPEUTICS | 2020年 / 42卷 / 10期

关键词：

antiemetics; carboplatin; chemotherapy-induced nausea and vomiting (CINV); patient-related risk factors; receiver operating characteristic (ROC); CHEMOTHERAPY-INDUCED NAUSEA; MODERATELY EMETOGENIC CHEMOTHERAPY; DOUBLE-BLIND; APREPITANT; PREVENTION; EFFICACY; PALONOSETRON; MULTICENTER; PACLITAXEL; OLANZAPINE;

D O I：

10.1016/j.clinthera.2020.08.007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Purpose: This study aimed to identify patient-related risk factors for chemotherapy-induced nausea and vomiting (CINV) in patients with cancer receiving carboplatin in addition to standard antiemetics, using real-world data. Methods: In this single-center, observational study, data from electronic medical records of consecutive patients with solid tumors who had received their first cycle of a carboplatin-based regimen and were treated with a 2- or 3- drug combination of antiemetics from January 2014 to January 2019 at Toranomon Hospital were retrospectively analyzed. The primary end point was the occurrence of a complete response (CR) within 5 days after the first cycle, which was defined as no vomiting and no use of rescue medication for CINV. A receiver operating characteristic curve, univariable, and multivariable logistic regression analyses were used. Findings: A total of 314 patients were evaluated in this study. The proportion of patients who had a CR in the overall, acute, and delayed phases was 76.8% (n = 241), 98.7% (n = 310), and 77.4% (n = 243), respectively. Similar to univariable logistic regression analysis, multivariable logistic regression analysis revealed that age >= 70 years and total dexamethasone dose >= 14.6 mg were significantly associated with a non-CR in the overall phase, whereas female sex, history of habitual alcohol intake, and history of smoking were not associated with a non-CR in the overall phase. (C) 2020 Elsevier Inc.

引用

页码：1975 / 1982

页数：8

共 26 条

[1] 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting [J].